TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18308908

Group type: EXPERIMENTAL
Intervention: Training for case managers to manage substance use disorders
Number of subjects: 232

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 232

Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 232
Study: 16240429

Group type: EXPERIMENTAL
Intervention: Cervical tourniquet (number 1 polyglactin suture tied around the cervix)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 28
Study: 12142655

Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 814

Group type: COMPARATOR
Intervention: Standard closure methods
Number of subjects: 814
Study: 10201462

Group type: EXPERIMENTAL
Intervention: Clarithromycin plus omeprazole
Number of subjects: 1151

Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 1151

Group type: COMPARATOR
Intervention: Ranitidine alone
Number of subjects: 1151
Study: 8522724

Group type: EXPERIMENTAL
Intervention: PDEX (dexamethasone)
Number of subjects: 68

Group type: COMPARATOR
Intervention: P (saline placebo)
Number of subjects: 68
Study: 2141590

Group type: EXPERIMENTAL
Intervention: Ingelheim M inhalator
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Berodual Inhaletten
Number of subjects: 60
Study: 41548

Group type: EXPERIMENTAL
Intervention: Clobazam (30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipotassium chlorazepate (15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31421295

Group type: EXPERIMENTAL
Intervention: Hypothyroidism present in patients with hypertensive intracerebral hemorrhage (54 patients, 23.4%)
Number of subjects: 462

Group type: COMPARATOR
Intervention: No hypothyroidism in matched controls (33 patients, 14.3%)
Number of subjects: 462
Study: 31023750

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training, twice a week for 12 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 44
Study: 27839705

Group type: EXPERIMENTAL
Intervention: Red wavelength LLLT (628 nm)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Infrared wavelength LLLT (828 nm)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Heat treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: No heat-light (control) treatment
Number of subjects: 16
Study: 26058589

Group type: EXPERIMENTAL
Intervention: Lenalidomide and vorinostat
Number of subjects: 16
Study: 23261048

Group type: EXPERIMENTAL
Intervention: 5-valent oral rotavirus vaccine (3 doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21323475

Group type: EXPERIMENTAL
Intervention: NASAL-18 technique
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional method (control)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NASAL-18 group
Number of subjects: 48
Study: 19185772

Group type: EXPERIMENTAL
Intervention: Vitality Diet (VD) - low-sodium DASH-type diet including 6 servings of 100 g cooked lean red meat per week
Number of subjects: 111

Group type: COMPARATOR
Intervention: Reference Healthy Diet (RHD) - higher acid load diet based on general dietary guidelines
Number of subjects: 111
Study: 17098874

Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Guided progressive relaxation (Control)
Number of subjects: 12
Study: 15200448

Group type: EXPERIMENTAL
Intervention: Intervention group (prophylactic repair of AV graft stenosis)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Observation group (repair only in the event of thrombosis)
Number of subjects: 64
Study: 11276032

Group type: EXPERIMENTAL
Intervention: Mixture model methodology for handling non‐ignorable drop‐outs in longitudinal studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixture model for non‐ignorable drop‐outs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linear model for the conditional mean of the outcome vector given time of drop out
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parameterization of the general linear mixture model
Number of subjects: 0
Study: 9042119

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg first dose, 0.3 mg/kg for the next 2 mornings)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (equal volume, identical appearance)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 8159441

Group type: EXPERIMENTAL
Intervention: Ketamine (250 mcg/kg i.v. slow push)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of ketamine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Single-dose injections of ketamine
Number of subjects: 6
Study: 3124047

Group type: EXPERIMENTAL
Intervention: Dantrolene sodium (1.5 mg/kg per day)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 31900231

Group type: EXPERIMENTAL
Intervention: Your Heart Forecast (YHF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 28815341

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa once weekly (QW)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa every 2 weeks (Q2W)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study: 26686309

Group type: EXPERIMENTAL
Intervention: Enoxaparin 4000 IU
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Enoxaparin 6000 IU
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Enoxaparin 2×4000 IU
Number of subjects: 164
Study: 25659956

Group type: EXPERIMENTAL
Intervention: ADV1
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: ADV2
Number of subjects: 288

Group type: COMPARATOR
Intervention: DET
Number of subjects: 288
Study: 23073362

Group type: EXPERIMENTAL
Intervention: High levels of attachment-related avoidance
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low to moderate levels of attachment-related avoidance
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Attachment-related anxiety
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Attachment dimensions
Number of subjects: 65
Study: 20135832

Group type: EXPERIMENTAL
Intervention: Topical lidocaine‐prilocaine mixture
Number of subjects: 46

Group type: COMPARATOR
Intervention: No topical anesthesia (Control)
Number of subjects: 46
Study: 18204342

Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg daily for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg daily
Number of subjects: 20
Study: 16616973

Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control
Number of subjects: 253
Study: 15030297

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aldosterone inhibition and combination therapy (ACEI/ARB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel therapies targeting post-translational endothelial and mesangial messengers
Number of subjects: 0
Study: 10686575

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8884309

Group type: EXPERIMENTAL
Intervention: Canrenoate potassium (200mg in 10ml saline solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (10ml saline solution)
Number of subjects: 30
Study: 2071559

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Trazodone (250 mg/day)
Number of subjects: 126
Study: 6851419

Group type: EXPERIMENTAL
Intervention: Coughing
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mental tasks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mueller and Valsalva manoeuvres
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Coughing during expiration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Chemical stimulation (inhalation of citric acid)
Number of subjects: 8
Study: 30887844

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus Panitumumab
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus Bevacizumab
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus anti-EGFR combinations
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 19
Study: 30054587

Group type: EXPERIMENTAL
Intervention: Plastic bag with standard care
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Portable thermal nest (PTN) with standard care
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 300
Study: 25385307

Group type: EXPERIMENTAL
Intervention: Colder water (5, 7, 10°C)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Electric‐cooled apparatus
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Age group 12 to 14 years
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Age group 10 to 11 years
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 113
Study: 25404438

Group type: EXPERIMENTAL
Intervention: T-tube insertion
Number of subjects: 148

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 148
Study: 22561099

Group type: EXPERIMENTAL
Intervention: SES (n = 20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham stimulation (n = 18)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: SES
Number of subjects: 38
Study: 19890250

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18327510

Group type: EXPERIMENTAL
Intervention: Shift work
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Shift work with baseline SBP > or = 140 mmHg and an additional increase
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Physical workload
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Noise exposure
Number of subjects: 1288

Group type: COMPARATOR
Intervention: No exposure (day workers)
Number of subjects: 1288
Study: 15724758

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with Atrisorb resorbable membrane
Number of subjects: 10

Group type: COMPARATOR
Intervention: Open flap debridement (control)
Number of subjects: 10
Study: 11394391

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) with the basement membrane side against the root (AB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM) with the connective tissue side against the root (AC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both AB and AC sites
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both treatments (AB and AC)
Number of subjects: 10
Study: 9885088

Group type: EXPERIMENTAL
Intervention: Telephone-based counseling intervention delivered by the Cancer Information and Counseling Line (CICL) including 16 telephone outcalls over a 12-month period.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 400
Study: 7993324

Group type: EXPERIMENTAL
Intervention: Cognitive techniques program for preventing depressive symptoms
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study: 2500068

Group type: EXPERIMENTAL
Intervention: UFT-MMC therapy (400 or 600 mg/day of UFT, plus 6 or 8 mg/body of MMC intravenously weekly for three weeks, then triweekly after six weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: UFT-ACR therapy (400 or 600 mg/day of UFT, plus 20 mg/body of ACR intravenously for 5 serial days every three weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study: 7933495

Group type: EXPERIMENTAL
Intervention: New intraoperative fluid infusion at 5, 10 ml.kg‐1.h‐1 for 3 hours
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: New intraoperative fluid infusion at 15 ml.kg‐1.h‐1 for 2 hours
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: New intraoperative fluid infusion
Number of subjects: 18
Study: 639574

Group type: EXPERIMENTAL
Intervention: Keratolytic gel treatment
Number of subjects: 0
Study: 30251137

Group type: EXPERIMENTAL
Intervention: Short dry lab training prior to surgery
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no prior training)
Number of subjects: 39
Study: 28708072

Group type: EXPERIMENTAL
Intervention: CF fortified with 2 mg NaFeEDTA plus 3.8 mg FeFum for six days/week (n = 126)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: CF fortified with 2 mg NaFeEDTA and 3.8 mg FePP for six days/week (n = 127)
Number of subjects: 378

Group type: COMPARATOR
Intervention: No food intervention (n = 125)
Number of subjects: 378
Study: 25864858

Group type: EXPERIMENTAL
Intervention: Silica-gold nanoparticles (NP) in a bioengineered on-artery patch
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Silica-gold iron-bearing NP with targeted micro-bubbles and stem cells using a magnetic navigation system
Number of subjects: 180

Group type: COMPARATOR
Intervention: Stent implantation
Number of subjects: 180
Study: 24089379

Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 21777745

Group type: EXPERIMENTAL
Intervention: Surgical minithoracotomic LV lead implantation (Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transvenous LV lead implantation (Group 2)
Number of subjects: 40
Study: 19302516

Group type: EXPERIMENTAL
Intervention: Parent-to-parent consultation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 20
Study: 17505029

Group type: EXPERIMENTAL
Intervention: Whole-blood interferon-gamma ELISA (QuantiFERON-TB Gold [QFT-G])
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Interferon-gamma enzyme-linked immunospot assay (T SPOT.TB)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 144
Study: 15452837

Group type: EXPERIMENTAL
Intervention: Prasterone 200 mg/day
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 11445487

Group type: EXPERIMENTAL
Intervention: High-dose isoxsuprine hydrochloride (60 mg/day orally)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9669262

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 576
Study: 7818725

Group type: EXPERIMENTAL
Intervention: Acarbose (3 x 50 mg day‐1 for days 1-3; 3 x 100 mg day‐1 for days 4-7)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3291444

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 10
Study: 31981498

Group type: EXPERIMENTAL
Intervention: Screened patients (n=99)
Number of subjects: 8935

Group type: COMPARATOR
Intervention: Unscreened patients (n=516)
Number of subjects: 8935
Study: 31556978

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus placebo
Number of subjects: 9006

Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 9006
Study: 28612453

Group type: EXPERIMENTAL
Intervention: Low-intensity 4-week intervention including compassion, mindfulness, and acceptance practices
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 20
Study: 25773919

Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA)
Number of subjects: 10003

Group type: COMPARATOR
Intervention: Functional testing (exercise electrocardiography, nuclear stress testing, or stress echocardiography)
Number of subjects: 10003

Group type: EXPERIMENTAL
Intervention: CTA
Number of subjects: 10003

Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 10003
Study: 23527561

Group type: EXPERIMENTAL
Intervention: Ghrelin infusion (15 pmol kg(‐1) min(‐1) for 3 hours before and on day 2 after surgery)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ghrelin infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 24
Study: 21844318

Group type: EXPERIMENTAL
Intervention: Fidaxomicin (200 mg b.i.d.)
Number of subjects: 1164

Group type: COMPARATOR
Intervention: Vancomycin (125 mg q.i.d.)
Number of subjects: 1164

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 1164
Study: 19552869

Group type: EXPERIMENTAL
Intervention: Pharmacologic and psychotherapeutic treatments
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Severity of self‐rated pretreatment suicidal ideation (Suicidal Ideation Questionnaire adapted for adolescents score >= 31)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Severity of depressive symptoms (Reynolds Adolescent Depression Scale score >= 91)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Clinical Global Impressions‐Severity of Illness scale score
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Clinical Global Impressions‐Improvement scale score
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Specific interpersonal stressors
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Suicidal events
Number of subjects: 439
Study: 16955616

Group type: EXPERIMENTAL
Intervention: Novel technique for microimplant placement
Number of subjects: 41

Group type: COMPARATOR
Intervention: Established method (control technique)
Number of subjects: 41
Study: 15700744

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid/silver sulfadiazine cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silver sulfadiazine cream alone
Number of subjects: 0
Study: 10802273

Group type: EXPERIMENTAL
Intervention: GyneFix IUD
Number of subjects: 600

Group type: COMPARATOR
Intervention: TCu380A IUD
Number of subjects: 600
Study: 9395681

Group type: EXPERIMENTAL
Intervention: Conventional research techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trial (RCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative methodologies
Number of subjects: 0
Study: 1312769

Group type: EXPERIMENTAL
Intervention: MIP (mytomicin, ifosfamide, cisplatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carboplatin (substituted for cisplatin in MIP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VIP (vindesine, ifosfamide, cisplatin)
Number of subjects: 0
Study: 3919352

Group type: EXPERIMENTAL
Intervention: Nicotine-containing chewing gum (2.0 mg)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Nicotine-containing chewing gum
Number of subjects: 193
Study: 29374780

Group type: EXPERIMENTAL
Intervention: Compression treatment (N=82)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Elevation (Control) (N=71)
Number of subjects: 153
Study: 27993804

Group type: EXPERIMENTAL
Intervention: Molecularly targeted agents (MTAs) based on tumor molecular profiling
Number of subjects: 741

Group type: COMPARATOR
Intervention: Treatment at physician's choice (TPC)
Number of subjects: 741
Study: 25667258

Group type: EXPERIMENTAL
Intervention: 24-hour schedule
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 16-hour schedule
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 12-hour schedule
Number of subjects: 49
Study: 24023027

Group type: EXPERIMENTAL
Intervention: FORE‐SIGHT® (Casmed, Branford, CT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: INVOS® 5100C (Covidien, Boulder, CO)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: NIRO‐200NX® (Hamamatsu Photonics, Hamamatsu City, Japan)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: EQUANOX® 7600 (3‐wavelength version)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: EQUANOX® 7600 (4‐wavelength version)
Number of subjects: 23
Study: 21437317

Group type: EXPERIMENTAL
Intervention: Active after-sun (AS) lotion containing DNA-repair enzymes (photolyase from Anacystis nidulans and Micrococcus luteus extract with endonuclease activity)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Untreated test fields
Number of subjects: 14

Group type: COMPARATOR
Intervention: SPF30 sunscreen
Number of subjects: 14
Study: 18242722

Group type: EXPERIMENTAL
Intervention: ALN-RSV01 (150mg, single dose and for five daily doses)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 101
Study: 16774662

Group type: EXPERIMENTAL
Intervention: CAPE42 self-report instrument
Number of subjects: 765
Study: 14515596

Group type: COMPARATOR
Intervention: Whitening strips (6% hydrogen peroxide)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Paint-on gel (18% carbamide peroxide)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Whitening dentifrice (no peroxide)
Number of subjects: 48
Study: 10028214

Group type: EXPERIMENTAL
Intervention: Trait Anger scale
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Self‐report anger scales
Number of subjects: 65
Study: 7722912

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flurbiprofen vehicle
Number of subjects: 0
Study: 2029499

Group type: EXPERIMENTAL
Intervention: Unfiltered boiled coffee (lipid content, 1.0 g/l)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Boiled and filtered coffee (0.02 g lipid/l)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No coffee
Number of subjects: 64
Study: 6268783

Group type: EXPERIMENTAL
Intervention: Harmogen (piperazine oestrone sulphate)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31208770

Group type: EXPERIMENTAL
Intervention: Opening the lung strategy ventilation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (ventilated as ARDS net)
Number of subjects: 66
Study: 28246175

Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA) plus standard care
Number of subjects: 4146

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4146
Study: 26088043

Group type: EXPERIMENTAL
Intervention: Water and education provision (WEP) group
Number of subjects: 240

Group type: COMPARATOR
Intervention: Education provision (EP) group
Number of subjects: 240